Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735960 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15 | |
| SCHEMBL758172 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15 | |
| SCHEMBL7941629 | 0.92 | L3MBTL3 (0.41) | SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15 | |
| SCHEMBL23943467 | 0.88 | KDM4E (0.44) | ALDH1A1KDM4EALOX15MEN1KMT2A | |
| SCHEMBL26112778 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4EOPRL1L3MBTL3 | |
| SCHEMBL26112782 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4EOPRL1L3MBTL3 | |
| SCHEMBL3168997 | 0.87 | — | — | |
| SCHEMBL22179798 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1OPRL1L3MBTL3L3MBTL1 | |
| SCHEMBL18727450 | 0.86 | KDM4E (0.36) | SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15 | |
| SCHEMBL26820274 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1OPRL1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023142754-A1 | EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY | 江苏天士力帝益药业有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| WO-2006114371-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ROS1, CDK9, GRK4 | SMN1; SMN2 4114/4885ALDH1A1 3619/4885KDM4E 755/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | SMN1; SMN2 4001/4885ALDH1A1 1538/4885KDM4E 2994/4885 |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 3442/4885ALDH1A1 3351/4885KDM4E 521/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | SMN1; SMN2 4001/4885ALDH1A1 1538/4885KDM4E 2994/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | SMN1; SMN2 2209/4885ALDH1A1 1348/4885KDM4E 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.